title: Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk.
abstract: BACKGROUND
  Postmortem studies suggest that fibrillar brain amyloid places people at higher risk for hazardous driving in the preclinical stage of Alzheimer's disease (AD).
  
  
  METHODS
  We administered driving questionnaires to 104 older drivers (19 AD, 24 mild cognitive impairment, and 61 cognitive normal) who had a recent18F-florbetapir positron emission tomography scan. We examined associations of amyloid standardized uptake value ratios with driving behaviors: traffic violations or accidents in the past 3 years.
  
  
  RESULTS
  The frequency of violations or accidents was curvilinear with respect to standardized uptake value ratios, peaking around a value of 1.1 (modelr2= 0.10,P= .002); moreover, this relationship was evident for the cognitively normal participants.
  
  
  CONCLUSIONS
  We found that driving risk is strongly related to accumulating amyloid on positron emission tomography, and that this trend is evident in the preclinical stage of AD. Brain amyloid burden may in part explain the increased crash risk reported in older adults.
authors.affiliation: Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA; Department of Neurology, Rhode Island Hospital, Providence, RI, USA.
authors.forename: Brian R
authors.initials: BR
authors.lastname: Ott
authors.affiliation: Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA; Department of Neurology, Rhode Island Hospital, Providence, RI, USA; Department of Psychiatry and Human Behavior, Rhode Island Hospital, Providence, RI, USA.
authors.forename: Richard N
authors.initials: RN
authors.lastname: Jones
authors.affiliation: Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA; Department of Diagnostic Imaging, Rhode Island Hospital, Providence, RI, USA.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Noto
authors.affiliation: Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA; Department of Diagnostic Imaging, Rhode Island Hospital, Providence, RI, USA.
authors.forename: Don C
authors.initials: DC
authors.lastname: Yoo
authors.affiliation: Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA; Department of Neurology, Rhode Island Hospital, Providence, RI, USA.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Snyder
authors.affiliation: Department of Neurology, Rhode Island Hospital, Providence, RI, USA.
authors.forename: Justine N
authors.initials: JN
authors.lastname: Bernier
authors.affiliation: Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Department of Medicine and Neurology, Washington University School of Medicine, St. Louis, MO, USA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: David B
authors.initials: DB
authors.lastname: Carr
authors.affiliation: Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Department of Medicine and Neurology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Roe
keywords: Alzheimer's disease; Assessment of cognitive disorders; Biomarkers; Cognitive aging; Dementia; Driving; MCI (mild cognitive impairment)